{"id":6140,"date":"2025-03-26T15:32:14","date_gmt":"2025-03-26T12:32:14","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6140"},"modified":"2025-03-26T15:32:14","modified_gmt":"2025-03-26T12:32:14","slug":"summary-of-vutrisiran-amvuttra-fda-approval-of-amyloid-cardiomyopathy-attr-cm","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/summary-of-vutrisiran-amvuttra-fda-approval-of-amyloid-cardiomyopathy-attr-cm\/","title":{"rendered":"Summary of Vutrisiran (Amvuttra) FDA Approval of amyloid cardiomyopathy (ATTR-CM)."},"content":{"rendered":"<div>Summary of Vutrisiran (Amvuttra) FDA Approval of amyloid cardiomyopathy (ATTR-CM).<\/div>\n<div><span> 1. Alnylam Pharmaceuticals received FDA approval for vutrisiran (Amvuttra) to treat transthyretin amyloid cardiomyopathy (ATTR-CM). It was previously approved for polyneuropathy of hereditary ATTR amyloidosis (hATTR-PN).<\/span><\/div>\n<div><span> 2. Clinical Trial Evidence: The approval was based on results from the HELIOS-B trial, published in The New England Journal of Medicine (August 2024). The study involved 655 patients, showing reductions in all-cause mortality, recurrent cardiovascular events, and improved quality of life.<\/span><\/div>\n<div><span> 3.Treatment Regimen &amp; Cost: Vutrisiran requires four subcutaneous doses per year, with an annual cost of $477,000. The company expects insurance coverage for up to 99% of patients, similar to its coverage for hATTR-PN.<\/span><\/div>\n<div><span> 4. Growing ATTR-CM Treatment Market: Previously, Pfizer\u2019s tafamidis (Vyndaqel, Vyndamax) was the only available ATTR-CM treatment. In November 2024, BridgeBio\u2019s acoramidis (Attruby) was also approved, increasing treatment options.<\/span><\/div>\n<div><span> 6. Patient Advocacy Response: Amyloidosis Support Groups welcomed the approval, emphasizing the continued unmet needs of ATTR-CM patients and the positive impact of new treatment options.<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Summary of Vutrisiran (Amvuttra) FDA Approval of amyloid cardiomyopathy (ATTR-CM). 1. Alnylam Pharmaceuticals received FDA approval for vutrisiran (Amvuttra) to treat transthyretin amyloid cardiomyopathy (ATTR-CM). It was previously approved for polyneuropathy of hereditary ATTR amyloidosis (hATTR-PN). 2. Clinical Trial Evidence: The approval was based on results from the HELIOS-B trial, published in The New England [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6140","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6140"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6140\/revisions"}],"predecessor-version":[{"id":6141,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6140\/revisions\/6141"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}